EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial

A LeMoire iD, R Replogle iD, L Shinn iD, A Kamil, L Lin iD, A P Kuttenkeuler, J Baisley, J Wang, S-A Girard iD, S Recker iD, A Bier

Beneficial Microbes · 2025

DOI: 10.1163/18762891-bja00072 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Beneficial Microbes, 2025. Verfasst von A LeMoire und 10 weiteren Autor:innen. Beteiligte Einrichtung: 419393Nutrasource Pharmaceutical and Nutraceutical Services, Inc. Guelph, ON, Canada. Hauptthemen laut MEDLINE: Feces, Bacillus coagulans, Probiotics, Defecation. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PepsiCo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Digestive health issues, including irregular bowel movements (BM) and gastrointestinal (GI) symptoms, affect millions of people in the United States and are associated with higher risks of various diseases. This randomized, double-blind, placebo-controlled study investigated the potential of Bacillus coagulans Unique IS2 to improve stool characteristics and reduce GI symptoms. Following a 2-week run-in, 144 healthy adults were randomized in a 1:1 ratio to either B. coagulans Unique IS2 (2 billion colony forming units/day) or placebo for 4 weeks. Participants were included if they had an average weekly complete spontaneous bowel movement (SBM) of ≥3.0 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FecesBacillus coagulansProbioticsDefecationHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedGastrointestinal MicrobiomeYoung AdultQuality of LifeHealthy Volunteers

Autor:innen und Institutionen

  • 419393Nutrasource Pharmaceutical and Nutraceutical Services, Inc. Guelph, ON, Canada.
  • PepsiCo Inc., Old Post Office, 433 W Van Buren St. Chicago, IL 60607, USA.
  • Apex Trials, Guelph, ON, Canada.

ORCID-Profile: A LeMoire, R Replogle, L Shinn, L Lin, S-A Girard, S Recker

Förderung

  • PepsiCo

Zitieren

APA

LeMoire, A., Replogle, R., Shinn, L., Kamil, A., Lin, L., Kuttenkeuler, A. P., Baisley, J., Wang, J., Girard, S. A., Recker, S., & Bier, A. (2025). Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Beneficial Microbes. https://doi.org/10.1163/18762891-bja00072

Vancouver

LeMoire A, Replogle R, Shinn L, Kamil A, Lin L, Kuttenkeuler AP, et al. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Beneficial Microbes. 2025. doi:10.1163/18762891-bja00072

BibTeX
@article{LeMoire2025,
  author = {LeMoire, A and Replogle, R and Shinn, L and Kamil, A and Lin, L and Kuttenkeuler, A P and Baisley, J and Wang, J and Girard, S-A and Recker, S and Bier, A},
  title = {Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial},
  journal = {Beneficial Microbes},
  year = {2025},
  doi = {10.1163/18762891-bja00072}
}
Kostenlos starten →